Trinchieri Vito, Marazzato Massimiliano, Ceccarelli Giancarlo, Lombardi Francesca, Piccirilli Alessandra, Santinelli Letizia, Maddaloni Luca, Vassalini Paolo, Mastroianni Claudio Maria, d'Ettorre Gabriella
Department of Public Health and Infectious Diseases Sapienza, University of Rome, 00185 Rome, Italy.
Department of Life, Health & Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Biomedicines. 2022 Aug 1;10(8):1851. doi: 10.3390/biomedicines10081851.
Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival.
This "real life" study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB).
At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level.
This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications.
尽管持续气道正压通气（CPAP）在与新冠病毒肺炎的时间赛跑中很有用，但它无法在严重肺损伤所施加的生理极限之上提供氧气。在先前的研究中，我们报告称，给予SLAB51益生菌可通过激活氧节约机制，为对生存至关重要的器官提供额外氧气，从而降低重症新冠病毒肺炎患者发生呼吸衰竭的风险。
这项“真实生活”研究是对因新冠病毒肺炎继发低氧性急性呼吸衰竭而接受CPAP治疗的新冠病毒感染患者进行的回顾性分析。将一组采用临时常规治疗（RUT）管理的患者与另一组接受RUT联合SLAB51口服细菌疗法（OB）治疗的患者进行比较。
在基线时，接受SLAB51治疗的患者的血液氧合水平显著低于对照组。在治疗3天后观察到相反的情况，尽管服用SLAB51的患者所接受的氧气量显著减少。在第7天，观察到服用益生菌组中需要CPAP治疗的新冠病毒肺炎患者的患病率较低。给予SLAB51是一种在全身水平改善氧合状况的补充方法。
本研究证明，给予益生菌可进一步促进缓解缺氧状况，从而限制CPAP的使用及其禁忌症。
